⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG)
businesswire.com
IONS
Age Related Macular Degeneration Market to Reach $16.2 billion by 2033, Globally, by 2034 at 5% CAGR: Allied Market Research
prnewswire.com
REGN
NVS
ROG
BIIB
CHRS
SNY
APLS
BHC
IONS
Form 8-K
sec.gov
IONS
Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs
businesswire.com
IONS
Ionis to present at upcoming investor conferences
businesswire.com
IONS
Ionis updates time for fourth quarter and full year 2025 financial results webcast
businesswire.com
IONS
Ionis updates time for fourth quarter and full year 2025 financial results webcast
businesswire.com
IONS
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
Ionis to hold fourth quarter and full year 2025 financial results webcast
businesswire.com
IONS
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
globenewswire.com
IONS
BIIB